Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease
Matteo Alessandro De Rosa, Dario Calisi, Mirella Russo, Astrid Thomas, Stefano Luca Sensi · 2026
Read Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease by Matteo Alessandro De Rosa, Dario Calisi, Mirella Russo, Astrid Thomas, Stefano Luca Sensi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13311910.txt.
Description
Matteo Alessandro De Rosa and co-authors detail a 2026 two-patient account of switching between under-skin levodopa infusion systems in advanced Parkinson's disease. No guidance existed for moving from ND0612 to foslevodopa/foscarbidopa.
Both patients used ND0612 plus oral levodopa before the switch. The new dose was set from total daily levodopa equivalents, then fine-tuned under close watch. Both switches finished within one day with no acute harms. At three months, off time had fallen sharply, with better movement, steadier sleep and behavior, and no infusion-site problems. The cases offer a practical template for clinics.
Catalog record
| CREATOR | Matteo Alessandro De Rosa, Dario Calisi, Mirella Russo, Astrid Thomas, Stefano Luca Sensi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20858 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |